Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Allecra: Secret weapon vs. bacteria

Allecra developing broad-spectrum solution to resistant Gram-negative bacteria

Allecra Therapeutic GmbHaims to develop a broad-spectrum solution to multidrug-resistant Gram-negative bacteria. The company will advance at least two preclinical compounds acquired from Orchid Chemicals & Pharmaceuticals Ltd., an Indian pharma, for a range of nosocomial infections.

Allecra raised €15 million ($19.6 million) in a series A round in April co-led by Edmond de Rothschild Investment Partners and Forbion Capital Partners, with participation by Orchid, EMBL Ventures and CEO Nicholas Benedict.

Benedict was CEO of Swiss women's health company Lumavita AG and, prior

Read the full 815 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers